Cernostics, a Pittsburgh, PA-based diagnostics company, raised $1.4m in Series B funding.
Backers included Novitas Capital, Geisinger Health System and the Pittsburgh Life Sciences Greenhouse.
The company intends to use the funds to accelerate the development and commercial sale of its lead product, TissueCypher: Barrett’s.
Led by Mike Hoerres, Chief Executive Officer, Cernostics is a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a new approach to tissue analysis.
Its TissueCypher: Barrett’s quantifies whole slide digital images to provide information and accuracy to gastroenterologists and pathologists and eliminate uncertainty related to the treatment of Barrett’s Esophagus.
August 9, 2012: Cernostics Receives $100K Loan from Ben Franklin Technology Partners of Northeastern Pennsylvania